share_log

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Officer Obenshain Andrew

SEC announcement ·  Mar 5 17:45
Summary by Moomoo AI
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 6,095 shares of common stock on March 4, 2024. The transaction was carried out in the open market with the shares sold at a price of $1.5276 each, resulting in a total sale value of $9,310.72. Following the sale, Obenshain's direct holdings in the company amount to 279,998 shares of common stock.
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 6,095 shares of common stock on March 4, 2024. The transaction was carried out in the open market with the shares sold at a price of $1.5276 each, resulting in a total sale value of $9,310.72. Following the sale, Obenshain's direct holdings in the company amount to 279,998 shares of common stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more